Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis
- Effect of Anti-Obesity Drug on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Yu-Hao Zhou; Xiu-Qiang Ma; Cheng Wu; Jian Lu; Shan-Shan Zhang; Jia Guo; Shun-Quan Wu; Xiao-Fei Ye; Jin-Fang Xu; Jia He // PLoS ONE;Jun2012, Vol. 7 Issue 6, p1
Background: Anti-obesity drugs are widely used to prevent the complications of obesity, however, the effects of antiobesity drugs on cardiovascular risk factors are unclear at the present time. We carried out a comprehensively systematic review and meta-analysis to assess the effects of...
- Smokeless tobacco and cardiovascular risk in non-Caucasian patients. Tully, R. P.; Zaheer, M.; Saha, B. // BJA: The British Journal of Anaesthesia;Jul2011, Vol. 107 Issue 1, p105
No abstract available.
- Second-Generation Antipsychotic Agents: A Review of Safety Profiles. Yurkov, Vladimir; Jha, Sarita; Collins, David M.; Alessi-Severini, Silvia // Current Psychiatry Reviews;Feb2012, Vol. 8 Issue 1, p49
Early clinical trials had suggested a better safety profile for the second-generation antipsychotics (SGAs; e.g. risperidone, olanzapine, quetiapine, aripiprazole) compared to the older first-generation agents (FGAs; e.g. haloperidol and phenothiazines); however, new long-term studies have...
- Rosiglitazone and the Risk of Adverse Cardiovascular Outcomes. Winterstein, A. G. // Clinical Pharmacology & Therapeutics;Jun2011, Vol. 89 Issue 6, p776
In this article the author discusses two, key studies reviewed by an advisory board of the U.S. Food and Drug Administration (FDA) on rosiglitazone and its cardiovascular risks. He says that both studies put the Medicare evaluation to be less problematic than the randomized clinical trial. He...
- Triple-Combination Pharmacotherapy for Medically III Smokers. Steinberg, Michael B.; Greenhaus, Shelley; Schmelzer, Amy C.; Bover, Michelle T.; Foulds, Jonathan; Hoover, Donald R.; Carson, Jeffrey L. // Annals of Internal Medicine;4/7/2009, Vol. 150 Issue 7, p447
Background: Smokers with medical illnesses are at particular risk for complications caused by tobacco. Clinical trial data on the effectiveness of triple-combination pharmacotherapy for tobacco dependence treatment in these high-risk smokers are not available. Objective: To evaluate extended...
- New evidence of CV risk with testosterone therapy. // Reactions Weekly;1/18/2014, Issue 1484, p3
The article reports on a research finding which indicate that men who received testosterone therapy had an increased risk of mortality and cardiovascular adverse events.
- Anagrelide use linked to cardiovascular risk. // Reactions Weekly;02/16/2013, Issue 1439, p4
The article reports on the addition of a warning to the labelling of Xagrid due to the risk cardiovascular adverse events in patients with essential thrombocytopaenia.
- Antihypertensive drugs may increase cholesterol patients' CVD risk. // Geriatrics;Nov99, Vol. 54 Issue 11, p71
Presents an abstract on the study, `Effect of hypertension and its treatment on lipid, lipoprotein (a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia,' by J.A. Papadakis, E.S. Ganotakis, et al, from the July 1999 issue of the American Journal of Hypertension.
- New Challenges Ahead for the Newer Oral Thrombin Inhibitors that Aim at Replacing Warfarin in Clinical Practice-Any Role for Scientific Societies in the Debate? Kaski, Juan-Carlos // Cardiovascular Drugs & Therapy;Aug2012, Vol. 26 Issue 4, p359
The author comments on a meta-analysis of trials which highlighted the association between thrombin inhibitors and increased risk of myocardial infarction (MI). According to the author, these findings have implication for both clinicians and the individual patient in a clinical setting. He...